RECURSION PHARMACEUTICALS, INC. Acquisitions, Net of Cash Acquired
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2024-12-31 was -$277.10M, a 390387.32% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2024-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $71.00K.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2023-09-30 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2025 was $0.00.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was -$277.10M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was -$1.84M.
- RECURSION PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | -$277.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$277.10M derived: sum of 2 quarters · filed 2026-02-25 | -$277.10M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $71.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.84M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.92M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$1.92M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.60M 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $2.60M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |